Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD4 | P21917 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455998 | 0.90 | HTR1A (0.53) | ALDH1A1SIGMAR1HTR1A | |
| SCHEMBL4326335 | 0.89 | DRD4 (0.53) | ALDH1A1DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL4324271 | 0.89 | ALDH1A1 (0.48) | ALDH1A1DRD2DRD4SIGMAR1 | |
| SCHEMBL4326085 | 0.86 | KCNH2 (0.53) | ALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL4329727 | 0.85 | ALDH1A1 (0.48) | ALDH1A1DRD4ADRA1DADRA1AADRA1B | |
| SCHEMBL4326331 | 0.85 | SMN1; SMN2 (0.52) | ALDH1A1DRD2DRD4DRD3ADRA1D | |
| SCHEMBL4464690 | 0.84 | ALDH1A1 (0.55) | ALDH1A1DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL4463803 | 0.84 | GAA (0.48) | ALDH1A1DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL4329231 | 0.82 | ALDH1A1 (0.44) | ALDH1A1DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL4330079 | 0.80 | ALDH1A1 (0.49) | ALDH1A1DRD4ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | ALDH1A1 1785/4885BCL2A1 4155/4885DRD2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.